European Polyp Surveillance Trial

Colorectal Neoplasms Clinical Trial

— EPoS  

Official title:

Randomized Controlled Trial of Comparison Between Surveillance Intervals After Excision of Colonic Adenomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02319928
• Other study ID #: AEG-EPOS-1
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 2015
• Est. completion date: December 2028

Study information

• Verified date: January 2021
• Source: Asociación Española de Gastroenterología
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This protocol describes the epos (ancient greek (Επος) for "story") of a group of related clinical trials aiming at addressing one of the most important unsolved challenges in the prevention of colorectal cancer (one of our major cancer killers); the surveillance of patients with premalignant polyps in the large bowel.

This project is timely because large scale colorectal cancer screening programmes are currently rolled out in most Western countries. These programmes are diagnosing large numbers of individuals with premalignant polyps (adenomas and serrated polyps). This creates both a diagnostic and resource dilemma, because the optimal surveillance strategy for these individuals to reduce future cancer risk is currently unknown..

The EPoS trials will randomize or register more than 20,000 individuals in different European countries to different surveillance colonoscopy intervals to disentangle the most effective and cost-effective surveillance strategy for the population. Subjects will be randomized according to their presenting polyp chracteristics The EPoS I trial randomizes patients with low-risk adenomas into 5 or 10-year surveillance; ; EPoS II randomizes patients with high-risk adenomas into 3 or 5-yearly surveillance ; EPoS III will include patients with serrated polyps in a one-arm study with surveillance after 5 and 10 years. The primary endpoint for all three trials is incidence of colorectal cancer after 10 years of follow-up.

This EPoS trials are the largest in polyp surveillance ever conducted. They address a clinical problem affecting hundreds of thousand individuals in Europe and the US each year, it has a large size, and should thus provide definitive results.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20000
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 74 Years

Eligibility

Inclusion Criteria:

• Cecal intubation (preferably documented by images/videoof the apendiceal orifice and the ileocecal valve; but not required).

• Adequate colonic cleansing, with Boston Bowel Cleansing Score equal or higher than 2 points in all colonic segments.

• Complete excision of all polyps at baseline colonoscopy findings (as judged by the trial endoscopists).

Exclusion Criteria:

• Lack of consent

• History of CRC or adenomas

• History of serrated polyps = 10 mm in diameter at any colorectal location or = 5 mm if located proximal to the splenic flexure

• Incomplete colonoscopy

• Incomplete endoscopic excision of polyps

• Genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)

• Inflammatory bowel disease

• History of surgical colon resection for any reason

• Severe co-morbidity with reduced life expectancy (NYHA 3-4)

• On-going cytotoxic treatment or radiotherapy for malignant disease

• Long-lasting attention and nursing services (somatic or psychosocial, mental retardation).

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Procedure:
• Colonoscopy

Locations

Country	Name	City	State
Spain	Hospital General Universitario de Alicante	Alicante

Sponsors (1)

Lead Sponsor	Collaborator
Asociación Española de Gastroenterología

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Colorectal cancer incidence	development of new colorectal cancer cases in the different arms of the trial	10 years